Mozart Therapeutics Overview

  • Founded
  • 2020
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $55M
Latest Deal Amount
  • Investors
  • 7

Mozart Therapeutics General Information

Description

Developer of an early-stage biopharmaceutical company intended to focus on developing novel immune engagers. The company is developing CD8 T-cell immune modulators for the treatment of autoimmune diseases as well as it specifically targets a subset of T-lymphocytes to delay the onset and ameliorate targeted autoimmune diseases, enabling doctors to administer state-of-the-art drugs for treating autoimmune disorders in patients.

Contact Information

Website
www.mozart-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 410 West Harrison Street
  • Suite 150
  • Seattle, WA 98119
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mozart Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 26-Oct-2021 $55M 0000 0000 Completed Generating Revenue
To view Mozart Therapeutics’s complete valuation and funding history, request access »

Mozart Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00 00 00 00.000
To view Mozart Therapeutics’s complete cap table history, request access »

Mozart Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Kathleen Fanning Chief Executive Officer & President
Kristine Swiderek Ph.D Chief Scientific Officer
Mark Davis Ph.D Founder
You’re viewing 3 of 4 executive team members. Get the full list »

Mozart Therapeutics Board Members (6)

Name Representing Role Since
Henrijette Richter Ph.D Sofinnova Partners Board Member 000 0000
Julie Gilmore Ph.D Self Board Member 000 0000
Lucio Iannone Ph.D Leaps by Bayer Board Member 000 0000
Peter Dudek Ph.D MRL Ventures Fund Board Member 000 0000
Steven Gillis Ph.D ARCH Venture Partners Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Mozart Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mozart Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Altitude Life Science Ventures Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Eli Lilly and Company Foundation Limited Partner Minority 000 0000 000000 0
Leaps by Bayer Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial